HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

M&A Market Heating Up As Economy “Stagnates,” C&D's Craigie Says

This article was originally published in The Rose Sheet

Executive Summary

Church & Dwight CEO Jim Craigie told analysts at the Goldman Sachs Consumer Products Symposium that as the economy continues to “stagnate,” a crop of new acquisition opportunities will arise in the consumer packaged goods arena.

You may also be interested in...



Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012

Johnson & Johnson pushes back to 2012 the target for returning its full slate of recalled OTC drugs to market as it adjusts to operating under a consent decree with FDA and the Department of Justice.

Simply Saline Acquisition Globalizes Church & Dwight's Nasal Hygiene Reach

Church & Dwight's planned acquisition of the Simply Saline line distributed in the U.S. will globalize the company's nasal hygiene category and serve as a model for other bolt-on acquisitions

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel